(S (NP (NP (NP (NNP Parkinson) (POS 's)) (NN disease)) (PRN (-LRB- -LRB-) (NP (NNP PD)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ common) (JJ neurological) (NN disorder)) (VP (VBN characterized) (PP (IN by) (NP (NN gait) (NN impairment)))))) (. .))
(S (S (NP (NNP PD)) (VP (VBZ has) (NP (DT no) (NN cure)))) (, ,) (CC and) (S (NP (NP (DT an) (NN impediment)) (PP (TO to) (S (VP (VBG developing) (NP (DT a) (NN treatment)))))) (VP (VBZ is) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (DT any) (JJ accepted) (NN method)) (SBAR (S (VP (TO to) (VP (VB predict) (NP (JJ disease) (NN progression) (NN rate))))))))))) (. .))
(S (NP (NP (DT The) (JJ primary) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB develop) (NP (NP (DT a) (NN model)) (VP (VBG using) (NP (NP (JJ clinical) (NNS measures)) (CC and) (NP (NP (JJ biomechanical) (NNS measures)) (PP (IN of) (NP (NP (NN gait)) (CC and) (NP (JJ postural) (NN stability)))))) (S (VP (TO to) (VP (VB predict) (NP (NP (DT an) (NN individual) (POS 's)) (NNP PD) (NN progression)) (PP (IN over) (NP (CD two) (NNS years)))))))))))) (. .))
(S (NP (NP (NNS Data)) (PP (IN from) (NP (CD 160) (NNP PD) (NNS subjects)))) (VP (VBD were) (VP (JJ utilized))) (. .))
(S (NP (NP (NN Machine) (NN learning) (NNS models)) (, ,) (PP (VBG including) (NP (NP (NN XGBoost)) (CC and) (NP (NNP Feed) (NNP Forward) (NNP Neural) (NNP Networks)))) (, ,)) (VP (VBD were) (VP (VBN developed) (S (VP (VBG using) (NP (JJ extensive) (NN model) (NN optimization) (CC and) (NN cross-validation)))))) (. .))
(S (NP (DT The) (ADJP (JJS highest) (NN performing)) (NN model)) (VP (VBD was) (NP (NP (DT a) (JJ neural) (NN network)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBD used) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (JJ clinical) (NNS measures))))) (, ,) (VP (VBD achieved) (NP (NP (DT a) (NNP PPV)) (PP (IN of) (NP (CD 71) (NN %)))) (PP (IN in) (S (VP (VBG identifying) (NP (JJ fast) (NNS progressors)))))) (, ,) (CC and) (VP (VBD explained) (NP (NP (DT a) (JJ large) (NN portion)) (PRN (-LRB- -LRB-) (NP (CD 37) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (NN variance)) (PP (IN in) (NP (NP (DT an) (NN individual) (POS 's)) (NN progression) (NN rate))) (PP (IN on) (NP (JJ held-out) (NN test) (NNS data)))))))))))) (. .))
(S (NP (DT This)) (VP (VBZ demonstrates) (NP (DT the) (JJ potential) (S (VP (TO to) (VP (VP (VB predict) (NP (JJ individual) (NNP PD) (NN progression) (NN rate))) (CC and) (VP (JJ enrich) (NP (NNS trials))) (PP (IN by) (S (VP (VBG analyzing) (NP (ADJP (JJ clinical) (CC and) (JJ biomechanical)) (NNS measures)) (PP (IN with) (NP (NN machine) (NN learning))))))))))) (. .))
